HIV VACCINE DESIGN AND DEVELOPMENT TEAM ? WYETH

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prototype recombinant vesicular stomatitis virus (rVSV) vectors expressing HIV/SIV antigens have been shown to elicit robust immune responses in rhesus macaques, and effect a significant reduction in viral load and alter disease pathogenesis following challenge with the simian-human immunodeficiency virus SHIV89.6P. However, when tested in a stringent non-human primate neurovirulence model, the prototype rVSV vector appeared to be inadequately attenuated for use in humans. Seven animals previously vaccinated in 2005 with VSV on this project were given a second DNA vaccine on 3/27/06 (the first was given in Oct. 2005). Mucosal samples and blood draws were collected to monitor immune response through May 2006. In January 2006, nineteen animals previously vaccinated in 2005 with VSV on this project were given another vaccination in January 2006. Blood samples, body temperature and mucosal samples were collected to monitor immune response. Twelve of the animals were released from the project in March 2006. The remaining seven animals received a final vaccination on 6/26/06. Samples were collected through August 2006 after which the animals were released from the project. Additional studies are planned using onlu Mamu Ao1 + monkeys to insure a strong immune response.